Sweaty feet can be caused by several factors, from lifestyle and shoewear to medical conditions. Here are the potential ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to include its use for the treatment of the rare cancer pheochromocytoma and ...

Merck & Co (NYSE:MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted priority review to its application for expanded use of the oral cancer drug Welireg.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

嗜铬细胞瘤（Pheochromocytoma，PHEO）作为一种罕见的肾上腺肿瘤，往往伴随着显著的儿茶酚胺分泌，应对其围术期管理的复杂性常令患者及其家属感到困惑。那么，嗜铬细胞瘤的围术期管理，包括麻醉管理，究竟有多重要呢？ 在手术治疗PHEO的过程中，麻醉管理更是 ...